We have developed and patent-protected a new protocol for preparation of tolerogenic DCs with particular properties, using high amounts of interferon-gamma. These cells represent a potential tool for preparing therapeutic cellular drugs - regulatory T lymphocytes that could be used for treatment of different immune diseses.
F.33 Slovenian patent
The proposed invention represents a new protocol for the assessment of agonism or antagonism of the existing and new synthetic inhibitors of the DC-SIGN lectin receptor expressed on dendritic cells (DCs). The assessment of the intrinsic activity of DC-SIGN inhibitors is based on the determination of cytokine profiles of DCs, being concomitantly exposed or unexposed to TLR agonists.
F.33 Slovenian patent
The invited speaker has presented the achievements of the project research group in the field of dendritic cell-based cellular preparations as potential therapeutics for cancer and other immune-based diseases.
B.04 Guest lecture